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Thecore region ofLPS has arelatively similar structure invariousGram-negative
bacteria, whereas the outermost O side chains are responsible for the marked anti-
genic diversityamongGram-negativebacteria. Oside chain-specific antibodies protect
against homologous strains but not against heterologous strains in animal models.
The core region ofLPS is exposed at the surface ofthe Oside chain-lacking rough
mutants, among which Escherichia coliJ5 and Salmonella minnesota R595 have been
the most studied. Afterimmunization with such mutants, antisera ofrabbits orhumans
contain antibodies directed against core LPS. These antisera have been reported
to protect against challenge with heterologous Gram-negative bacteria or smooth
LPS(1-5). Recent publicationsofcrossprotectionafforded by core USmAbs seemed
to support the concept that core LPS antibodies might have a role in the manage-
ment ofGram-negative infections. The crossprotection reported against cutaneous
Shwartzman reactions in rabbits or against Gram-negative bacterial peritonitis in
mice with an anti-lipid A human IgM mAb HA-1A (6) was so impressive that a
majormulticenter clinical study hasbeenundertaken inpatients with severe Gram-
negative bacteremia. The mechanisms ofthe postulated protection afforded by core
LPS antibodies remain, however, largely unknown. Whereas O side chain-specific
antibodies have been shown to increase the serum bactericidal activity against ho-
mologous Gram-negativebacteria and to increase the intravascular clearance ofho-
mologous bacteria or LPS (7, 8), core LPS antibodies did not increase significantly
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the serum bacterial activity against smooth Gram-negative bacteria and the intravas-
cular clearance of smooth bacteria or LPS (8).
It is now recognized that the biological effects of LPS are mainly mediated by
interactions with the immune system. TNF-a is released by LPS-stimulated macro-
phages, and, when secreted in high amounts, has been shown to be a pivotal medi-
ator of LPS-induced toxicity (9). IL-6 is another pleiotropic cytokine that appears
to be a key member of the cytokine network involved in the host responses to infec-
tion (10). In the present study, in order to investigate the mechanisms of protection
afforded by O side chains or core LPS antibodies, we determined whether these an-
tibodies would interfere with LPS-induced serum TNF or serum IL-6 production
in mice, and whether serum TNF or IL-6 levels would correlate with the protective
efficacy ofthese antibodies. We also reassessed the potential for crossprotection afforded
by polyclonal anti-E. coli J5 rabbit antiserum or by the anti-lipid A HA-lA mAb
against heterologous Gram-negative bacteria or LPS, using O side chain-specific
rabbit antisera as controls.
Materials and Methods
Bacteria and LPS
￿
The bacteria E. coli 0111:B4, its J5 mutant, and Pseudomonas aeruginosa
3 have been kindly provided by E. J . Ziegler (University of California Medical Center, San
Diego, CA). LPS from P. aeruginosa 3 was extracted in our laboratory with the hot phenol
water method. 0111 LPS and J5 LPS were commercially acquired (Sigma Chemical Co.,
St. Louis, MO; and Ribi ImmunoChem Research, Inc., Hamilton, MT).
Antisera.
￿
Female 2-3-kg New Zealand albino rabbits (Mad6rin, Fullinsdorf, Switzerland)
were vaccinated with stationary phase bacterial cells(E. coli, J5, E. coli 0111, or P. aeruginosa
3) heated to 100°C for 150 min and resuspended to a density of 5 x 109 bacteria/ml in
normal saline. Groups of five rabbits were injected with 1 ml of bacterial vaccines intrave-
nously three times weekly for 2 wk, and blood was collected 7 d afterthe last injection with
aseptic techniques. Sera were pooled, heated at 56°C for 30 min, and kept frozen at -20°C
until used.
mAb.
￿
HAAA is a human IgM mAb resulting from a fusion of heteromyeloma cells with
B lymphocytes from the spleen of a patient with Hodgkins disease immunized with E. coli
J5. Purified HA-lAwas provided by Merieux Institute (Lyon, France) and was prepared from
the clone originally isolated at Stanford University (6). LPS was not detectable with a chro-
mogenic Limulus assay (KabiVitrum, Stockholm, Sweden), which had a sensitivity of 12.5
pg LPS/ml.
Bioassay for TNF Serum Levels.
￿
A highly sensitive mouse fibrosarcoma cell line, WEHI
164 clone 13, a generous gift from J. Tschopp (InstituteofBiochemistry, Lausanne, Switzer-
land), was used to measure serum TNF levels, as originallydescribed by Espevik and Nissen-
Meyer (11). Twofold serial dilutions of mouse serum from 1 :100 to 1 :12,800 were tested in
duplicates, and the amount of TNF was extrapolated from a standard curve using mouse
rTNF kindly provided by B. Allet (Glaxo IMB, Carouge, Switzerland). The LD50 of clone
13 cells was between 1 and 3 pg mouse rTNF/ml. The specificity of the test was confirmed
by neutralization with a rabbit anti-mouse rTNF polyclonal antibody.
Bioassayfor IL-6 Serum Levels.
￿
IL-6 was measured using IL-6-dependent mouse-mouse
hybridoma cells 7TD1, kindly provided by J. Van Snick (Ludwig Institute, Brussels, Bel-
gium), according to his method (12). The limit of detection was <1 pg mouse rIL-6/ml.
Endotoxemic Lethality in Mice.
￿
Female 20-25-g C57BL/6 mice (Mad6rin) were acclima-
tized for 3-5 d before each experiment. 0.5 ml rabbit antisera, 100,ug HA-1A in 0.2 ml 1%
human albumin, or 0.2 ml of the vehicle albumin was injected in the tail vein 1 h before
subsequent intraperitoneal challenge with various doses of 0111 LPS, J5 LPS, or P. aeruginosa
3 LPS in 0.5 ml PBS containing 15 mg galactosamine. Groups of 8-10 mice were used to
determine the LD5o. For each experiment, groups of four mice without LPS, challenge wereBAUMGARTNER ET AL.
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included. Lethality was monitored until 96 h. Blood was collected in the retro-orbital plexus
1 and 3 h after the intraperitoneal challenge to measure serum TNF andIL-6 levels, respectively.
Mucin-hemoglobin Peritonitis Model in Mice.
￿
The procedure was similar to that of the en-
dotoxemic lethality model, except that female 20-25-g OFl mice (Mad6rin) were used and
that a suspension of bacteria (E. coli 0111 or P. aeruginosa 3) with mucin (Sigma Chemical
Co.) and hemoglobin (BBL Microbiology Systems, Cockeysville, MD) was injected in-
traperitoneally instead of LPS. The suspension of 15% mucin and 4°Jo hemoglobin in PBS
was prepared in advance, autoclaved, homogenized by sonication, and kept at -20°C in
aliquots.
Cutaneous Shwartzman Reactions in Rabbits.
￿
Groups of 10 female 1.5-1.8-kg New Zealand
rabbits (Mad6rin) were shaved along the side and submitted to a preparative intradermal
injection of 50 ug 0111 LPS. 22 h later, 10 ml rabbit antisera or 1 mg HA-1A diluted in 1
ml of 1% human albumin, or 1 ml vehicle albumin alone was injected intravenously. 2 h
later, rabbits were submitted to a provocative intravenous injection of 12 .5 lcg 0111 LPS. The
presence of hemorragic necrosis at the site of intradermal injection was assessed after 24 h.
The preparative and provocative doses of LPS were determined as the lowest doses still in-
ducing a cutaneous reaction in N80% of untreated rabbits.
Statistical Methods.
￿
The numbers of deaths or cutaneous Schwartzman reactions in ex-
perimental groups were compared with two-tailed X2 tests or Fisher exact tests when appro-
priate. Intergroups differences in TNF or IL-6 serum levels were compared with the non-
parametric Kruskall-Wallis test.
Results
Mortality, Serum TNF, and Serum IL-6 Levels in Mice after Challenge with LPS.
￿
In
C57BL/6J galactosamine-sensitized mice, the LD5o is very low for J5 LPS or 0111
LPS, thus providing the possibility to administer antibody in large molar excess over
LPS. AntiJ5 rabbit antiserum (J5RS)' protected against J5 LPS challenge. How-
ever, neither J5RS nor HA-1A increased the LD5o of 0111 LPS, whereas anti-0111
rabbit antiserum (0111RS) afforded a very significant protection (Table I). When
mice were challenged with 1.5 LD5o of P . aeruginosa 3 LPS (100 ng/mouse), the
numbers of survivors were 1 of 10 in the normal rabbit serum (NRS) group, 0 of
10 in the J5RS group, and 0 of 10 in the HA-lA group. In contrast, 10 of 10 mice
in the P . aeruginosa 3 rabbit antiserum group survived (p < 10-5).
In another experiment (Fig. 1), serum TNF levels were measured 1 h after chal-
lenge with 50 ng 0111 LPS (N10 LD5o). Levels were undetectable in the 10 mice
pretreated with 0111RS, including the two mice that died in this group. In the NRS-,
J5RS-, HA-IA-, or albumin-recipient mice, TNF levels ranging from 0.2 to 8.3 ng/ml
were detectable in all animals, except in one NRS-recipient mouse, which was the
only survivor from these four groups. No significant difference in TNF levels be-
tween these four nonprotected groups was observed, whereas the difference between
these groups and the 0111RS group was highly significant (lb < 10-5).
Similar findings were observed with serum IL-6 levels measured 3 h after chal-
lenge in the same experiment. Levels were undectable (<0.1 ng/ml) in the 10 mice
that received 0111RS. In all the other mice, levels were detectable: the median (range)
was 2.8 ng/ml (0.4-6.4) in the NRS group, 2.3 (0.8-5 .6) in theJ5RS group, 1.7 (0.8-4.8)
in the albumin group, and 1 .7 (0.8-3.2) in the HA-lA group. The lowest value (0.4
ng/ml) was found in the only surviving mouse from the NRS group. There was no
I Abbreviations used in this paper: J5RS, antiJ5 rabbit antiserum; NRS, normal rabbit serum; O111RS,
anti-0111 rabbit antiserum.892
￿
ANTILIPOPOLYSACCHARIDE ANTIBODIES AND PROTECTION
TABLE I
Protection against LPS A$orded in Galactosamine-sensitized C57BL16,J
Mice by Rabbit Antisera or by the Human IgM mAb HA-1A
' p < 0.01 ; the other comparisons between groups were not significant.
1 Anti-lipid A human IgM mAb (6).
significant difference between the four nonprotected groups, whereas thedifference
between these groups and the 011IRS group was highly significant (¢ < 10-4).
Experiments ofProtection InMucin-hemoglobin Peritonitis in Mice.
￿
Since we found that
J5RS and HA-1Adidnot improvethe survival of mice challenged with purified LPS,
we investigated whether these preparations would be more effective against chal-
lenge with living bacteria. In the peritonitis model, neitherJ5RS nor HA-1A in-
creased the LD50 of E. coli 0111 or P . aeruginosa 3 (a strain with a very low LD5o),
whereashomologous rabbit antisera afforded avery significant protection (Table II).
CutaneousShwartzman Reactionsin RabbitsafterChallengewith 0111 LPS
￿
We extended
our investigations to the Shwartzman reaction in rabbits because some of theoriginal
experiments of protection with J5RS and HA-1A have been performed using this
model. We found that the number of rabbits with a cutaneous hemorragic necrosis
was 8 of 10 after NRS administration, 8 of 10 afterJ5RS, 8 of 10 after albumin,
and 6 of8 after HA-1A (2 of 10 rabbits in this group died before 24 h). The hemor-
ragic necrosis were slightly weaker in theJ5RS group compared with the NRS, HA-
1A, or albumin groups. In contrast, only 4of 10 rabbits after0111RS showed a cuta-
neous reaction (p = 0.08).
Discussion
Although LPS can activate plasmatic mediators such as complement and contact
(Hageman) factors, there is increasing evidence that many ofthetoxic effects of LPS
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FIGURE 1.
￿
Serum TNF levels 1 h after intraperitoneal chal-
lenge of galactosamine-sensitized C57BL/6J mice with 50
ng 0111 LPS/mouse after prophylaxis with rabbit antisera
"
￿
or HA-lA mAb. Groups of 10 mice were pretreated 1 h be
e
￿
fore LPS challenge with 0.5 ml NM 0.5 mlJ5RS 0.5 ml
0111M 0.2 ml of 1% human albumin (ALB), or 100 ug
'
￿
human IgM mAb HA-lA diluted in 0.2 ml of 1% ALB per
mouse. The open circles represents survivors, and the close
,~
￿
circles represent nonsurvivors. The limit ofdetection ofTNF
"
￿
'
￿
in serum was 0.1 ng TNF/ml.
NRS J5RS 0111RS ALB HA-1A
Sera or mAb
LD5o
J5 LPS
after LPS challenge
0111 LPS
ng LPS/mouse
Nonimmune rabbit 2 4
AntiJ5 rabbit 214' 20
Anti-0111 rabbit - 500"
Human albumin - 4
HA-1 A1 - 2BAUMGARTNER ET AL.
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TABLE II
Protection against Gram-negative Bacteria Afforded in OF1 mice by
Rabbit Antisera or by the Human IgA-f'nzAb HA-JA
p < 0.01; the other comparisons between groups were not significant.
t Anti-lipid A human IgM mAb (6)
are mediated through activation of target cells in the immune system, especially
ofthe macrophage (9). With regard to the pathophysiology ofseptic shock, several
linesofevidence suggest that TNF is amongthemost important LPS-induced medi-
ators. First, the injection ofhigh doses of TNF to rats (13), mice (14), or rabbits
(15) reproduced the picture of septic shock. Second, the lethality of experimental
Gram-negative bacteremia or endotoxemia was prevented by the administration of
antiTNF antibodies (15-17). Last, high serum TNF levels correlated withthe mor-
tality ofpatients with meningococcemia (18) or septic shock (19). Therefore, an im-
portant mechanism ofprotection ofanti-LPS antibodies in vivo could be to prevent
the increased TNF serum levels due to the triggering oftarget cells by LPS. In the
present study, we found that Oside chain-specific rabbit antiserum markedly sup-
pressed theserum TNF induced by homologous LPS challenge and protected mice
from death. Thus, the suppression ofLPS-inducedserumTNFafter administration
oftype-specific antibodies might be an important mechanism leading to increased
survival. Incontrast, the twopreparationsofcore LPS antibodies, rabbitJ5 antiserum
and the anti-lipid A HA-lA mAb, had no detectable impact on serum TNF levels
and showed no protection compared with controls.
Another cytokine that may play an important role in the defense against septic
shock is IL-6. IL-6 expression is induced by LPS, by TNF, or by IL-1 in many cell
typessuch as fibroblasts, endothelial cells, and macrophages. Amongmany biologic
activities, IL-6 expands theproduction ofhematopoietic cells, enhances the produc-
tion ofhepatic acute phase proteins, and induces an elevation in body temperature
(10). In man, injection of LPS (20) or TNF (21) elicits increased circulating IL-6.
High serum levels ofIL-6 have been associated with death in patients with menin-
gococcemia (22) or Gram-negative septic shock (23). However, this correlation may
not represent a causal relationship between IL-6 and mortality, particularlyin view
ofthefact that, incontrast toTNF, theadministration ofhighdosesofIL-6 toanimals
is apparently not deleterious (W Fiers, personal communication). In the present
study, we found that LPS-induced IL-6 production in mice was suppressed by O
side chain-specific antibodies concomitantlywith TNF production, while core LPS
antibodies had no effect. The observed reduction ofLPS-induced IL-6 production
Sera or mAb
LD5o after bacterial
E. colt 0111
challenge _
P. aeruginosa 3
CFU/mouse
Nonimmune rabbit 1 .7 x 105 5
AntiJ5 rabbit 1 .3 x 105 7
Anti-0111 rabbit >4.5 x 106" -
Anti-P. aeruginosa 3 - >500'
Human albumin 4 x 104 <5
HA-1A1 9 x 104 <5894
￿
ANTILIPOPOLYSACCHARIDE ANTIBODIES AND PROTECTION
may have been either a consequence of the TNF reduction, since IL-6 can be in-
duced by TNF, or, alternatively, a direct effect of antibodies on the stimulation of
the IL-6 secretion by LPS.
Thereare at leasttwopossible mechanisms forthe in vivo reduction ofLPS-induced
TNF or IL-6 production by anti-LPS antibodies: opsonization or neutralization.
By opsonizing LPS or whole bacteria, antibodies might prevent LPS from reaching
sensitive target cells. Alternatively, by binding to LPS, antibodies may directly neu-
tralize the biologically active part of the molecule. Since the protection reported by
others with antisera to rough mutants could not be attributed to opsonization (8),
it was postulated that core LPS antibodies might neutralize LPS. However, recent
experimentsin vitro usingO side chain-specific and core LPS mAbs failed to confirm
this hypothesis (24), thus raisingdoubts about the existenceoftrue LPS-neutralizing
antibodies. In view of the absence of neutralization of LPS demonstrable in vitro
(24), one might hypothesize that the reduction of TNF and IL-6 production after
challenge ofmice with LPS in thepresent experimentsmight have been due to opso-
nization ofLPS by O side chain-specific antibodies. Such an hypothesis would need
confirmation .
Our data do not support a role for core LPS antibodies in the crossprotection
against Gram negative bacteria or LPS. Indeed, neither the polyclonal J5 rabbit
antiserum northehuman monoclonal IgM HA-IA protected againstchallenge with
the LPSfrom E. coil 0111 or P. aeruginosa 3 in galactosamine-sensitized mice, against
lethal peritonitis induced by these strains in mice, or against 0111 LPS challenge
in the cutaneous Shwartzman reaction in rabbits. Moreover, neitherJ5 rabbit an-
tiserumnortheHA-IA mAb prevented theproduction ofTNFor IL-6 in theserum
ofmice challenged with LPS, suggesting that thesepreparations do nothave theability
to prevent theinteractions between LPS and target cells in vivo. While these findings
contrast with data previously reported using very similar models (6), they are in
accordance with the results foundby others with core LPS antisera (25). Therefore,
there are several reasons to fear that the protection sometimes reported with core
LPS antisera or mAbs might not be real: the precise epitopes of the LPS molecule
responsible for the postulated crossreactions remain unknown, the mechanisms of
thepostulated crossprotection remain enigmatic, and the experimentsofprotection
give discrepant results. The existence or not of a crossprotection afforded by core
LPS antibodies is acrucial issue because major multicenter clinical trials with core
LPS mAbs are presently being performed. Should these trials fail to demonstrate
a clear-cut protection, in the light of the present study, the whole concept should
seriously be questioned.
Summary
Two-core LPS antibodies, the rabbit J5 polyclonal antiserum and the human
anti-lipid AIgM mAb HA-IA, did not improvethesurvival ofmice challenged with
E. coli 0111 or P . aeruginosa 3, or with the LPS extracted from them, and did not
decrease the incidenceofShwartzman reactionsin rabbits challenged with 0111 LPS.
In contrast, O side chain-specific rabbit antisera were protective in these models.
The protection afforded by O side chain-specific antisera againstendotoxin lethality
was associated with decreased LPS-induced serum TNF and IL-6 levels, whereas
core LPS antibodies had no effect on TNF or IL-6 levels. The absence of reductionofLPS-induced cytokines levels by core LPS antibodies suggests that these antibodies
are not able to prevent the interactions between LPS and target cells.
Receivedfor publication 20 November 1989.
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